Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 01:45PM GMT
Release Date Price: $11.13 (+1.58%)
Luca Issi
RBC Capital Markets, Research Division - Research Analyst

Great. Hello, everybody, and thank you for dialing in. My name is Luca Issi. I'm a senior biotech analyst here at RBC Capital Market. And today, it's our great privilege to have Sandy Macrae, CEO of Sangamo, for a fireside chat. Sandy, thanks so much for joining us today.

Questions & Answers

Luca Issi
RBC Capital Markets, Research Division - Research Analyst

And maybe before we dive into the specifics, we'll love if you can share your thoughts on your platform. It feels to me that these days, all the headlines are on CRISPR/Cas9. But maybe can you talk about your zinc finger protease platform and some of the differentiating features versus CRISPR/Cas9?

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Delighted to, and good morning. It's a privilege to lead Sangamo and a truly remarkable platform. Zinc fingers are the most common transcription factors in our body. And through its years of expertise, Sangamo

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot